Jpmorgan Chase & CO Landos Biopharma, Inc. Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.22 - $0.51 $358 - $831	-1,631 Reduced 72.75%	611 $0
Q3 2022 Nov 14, 2022	BUY	$0.67 - $1.26 $345 - $650	516 Added 29.9%	2,242 $1,000
Q2 2022 Aug 11, 2022	SELL	$0.6 - $1.5 $174,390 - $435,976	-290,651 Reduced 99.41%	1,726 $1,000
Q1 2022 May 11, 2022	SELL	$1.44 - $5.22 $10,424 - $37,787	-7,239 Reduced 2.42%	292,377 $432,000
Q4 2021 Feb 10, 2022	SELL	$4.7 - $15.0 $48,767 - $155,640	-10,376 Reduced 3.35%	299,616 $1.44 Million
Q3 2021 Nov 12, 2021	BUY	$9.77 - $15.77 $3.03 Million - $4.89 Million	309,992 New	309,992 $4.53 Million

Ticker LABP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,254,900
Description
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of u...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.